Journals / MN Kardiyoloji / 2002 / Cilt: 9 - Sayı: 1

The detection of the myocardial damage by cardiac troponin T in severe heart failure and the factors related with the myocardial damage

İleri kalp yetersizliğinde miyokardiyal hasarın kardiyak troponin T ile saptanması ve miyokardiyal hasarla ilişkili faktörler

Pages
14–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cardiac troponin T level is correlated to the severity of left ventricular systolic dysfunction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Myocardial damage occuring in severe heart failure related to low ejection fraction can be shown by cardiac troponins.
📊
Key Findings & Data:MATERIAL AND METHODS: Cardiac troponin T was measured in 44 patients who have NYHA class III-IV heart failure (heart failure group) and angiographically normal 20 subjects who do not have symptoms and findings of heart failure (control group).
💡
Conclusion & Impact:Cardiac troponin T level is correlated to the severity of left ventricular systolic dysfunction.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kalp debisi · zayıf · Strok volümü

Abstract

AIM: Myocardial damage occuring in severe heart failure related to low ejection fraction can be shown by cardiac troponins. In this study, it has been aimed to disclose the myocardial damage which can be occured in severe heart failure by the levels of the cardiac troponin T and to investigate the factors related with the myocardial damage. MATERIAL AND METHODS: Cardiac troponin T was measured in 44 patients who have NYHA class III-IV heart failure (heart failure group) and angiographically normal 20 subjects who do not have symptoms and findings of heart failure (control group). RESULTS: CK (51.0±24.5 U/L vs 82.5±74.8 U/L) and CK-MB (14.3±5.5 U/L vs 20.4±11.5 U/L) levels were similar in the two groups (p>0.05). In spite of the fact that cardiac troponin T was found negative in 8 of the patients with heart failure, cardiac troponin T was found in all the patients in the control group. The patients with heart failure were divided in two subgroups as cardiac troponin T positive or negative. CK (88.1±21.8 U/L vs 81.3±82.3 U/L) and CK-MB (20.0±1.9 U/L vs 20.5±12.7 U/L) levels were not different statistically in these subgroups (p>0.05). But the left ventricular ejection fraction (%23.8±3.3 vs %31.6±5.9) was detected lower in troponin positive subgroup (p=0.001). Additionally, logistic regression analysis showed that left ventricular ejection fraction is the significant predictor of the positivity of troponin (p=0.01, r=0.32). CONCLUSION: Some patients with severe heart failure develop myocardial damage which may be demonstrated by elevated blood cardiac troponin T level. Cardiac troponin T level is correlated to the severity of left ventricular systolic dysfunction.

Özet

AMAÇ: İleri kalp yetersizliğinde düşük ejeksiyon fraksiyonu ile ilişkili olarak oluşan miyokardiyal hasar kardiyak troponinlerle gösterilebilmektedir. Bu çalışmada, ileri kalp yetersizliğinde oluşabilecek miyokardiyal hasarı kardiyak troponin T düzeyi ile ortaya koymak ve miyokardiyal hasarla ilişkili faktörleri araştırmak amaçlanmıştır. GEREÇ ve YÖNTEM: NYHA klas III-IV kalp yetersizliği olan 44 hasta (kalp yetersizliği grubu) ile anjiyografik olarak normal olan, kalp yetersizliği semptom ve bulguları olmayan 20 kişide (kontrol grubu) kardiyak troponin T ölçüldü. BULGULAR: CK (51.0±24.5 U/L'ye karşı 82.5±74.8 U/L) ve CK-MB (14.3±5.5 U/L'ye karşı 20.4±11.5 U/L) düzeyleri iki grupta benzer bulundu (p>0.05). Fakat kalp yetersizliği olan hastaların 8'inde kardiyak troponin T pozitif bulunurken, kontrol grubundaki hastaların hepsinde negatif bulundu. Kalp yetersizliği olan hastalar troponin pozitif ve negatif olarak alt gruplara bölündü. CK (88.1±21.8 U/L'ye karşı 81.3±82.3 U/L) ve CK-MB (20.0±1.9 U/L'ye karşı 20.5±12.7 U/L) düzeyleri bu iki alt grupta istatistiksel olarak farklı değildi (p>0.05). Ancak troponin pozitif alt grubunda sol ventrikül ejeksiyon fraksiyonunun (%23.8±3.3'e karşı %31.6±5.9, p=0.001) daha düşük olduğu saptandı. Ayrıca lojistik regresyon analizi troponin pozitifliğinin önemli belirleyicisinin sol ventrikül ejeksiyon fraksiyonu olduğunu gösterdi (p=0.01, r=0.32). SONUÇ: İleri kalp yetersizliği olan bazı hastalarda artmış kan kardiyak troponin T düzeyi ile ortaya konabilen miyokard hasarı gelişir. Kardiyak troponin T düzeyi sol ventrikül sistolik fonksiyon bozukluğunun ağırlığı ile ilişkilidir.

🔖

Cite This Article

BALCI, B., YAZICI, M., YILMAZ, Ö., YEŞİLDAĞ, O., İBRAHİMOV, F., MERİÇ, M., ALBAYRAK, F. (2002). The detection of the myocardial damage by cardiac troponin T in severe heart failure and the factors related with the myocardial damage. MN Kardiyoloji, Cilt: 9 - Sayı: 1, 14–18. https://ajindex.com/articles/297642

References (14)

  1. Tombe PP. Altered conractile function in heart failure. Cardiovasc Res 1998; 37:367-80.
  2. Weil J, Eschenhagen T, Magnussen O, et al. Reduction of myocardial myoglobin in bovine cardiomyopathy. J Mol Cell Cardiol 1997; 29:743-51.
  3. Ricchiuti V, Zhang J, Apple FS. Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling. Clin Chem 1997; 43:990-5.
  4. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999; 138:646-53.
  5. Polanczyk CA, Lee TH, Cook EF. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. J Am Coll Cardiol 1998; 32:8-14.
  6. Haller C, Zehelein J, Müller-bandorf, Katus HA. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem 1998; 44:930- 8- Sparano JA, Wolff AC, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. Lancet 2000; 356:1947-8.
  7. Ricchiuti V, Voss EM, Ney A, Odland.M, Anderson PAW, Apple FS. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998; 44:1919-24.
  8. Missov E, Mair J. A novel biochemical approach to congestive heart failure: Cardiac troponin T. Am Heart J 1999; 138:95-9.
  9. Vecchia L, Mezzena G, Ometto R, et a.L Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997; 80:88-90.
  10. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
  11. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volum determinations: echocardiographic angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37:7-11. Declaration of Helsinki. Reccomendation guiding physicians in biomedical research involving human subjects. 41 st World Medical Assembly, Hong-Kong, September (1989)
  12. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96:2953-8.
  13. Müller-Bardorff M, Freitag H, Scheffold T, Remppis A, Kübler W, Katus HA. Development and characterization of a rapid assay for bedside determinations of cardiac troponin T. Circulation 1995;. 92:2869-75.
  14. Feuerstein G, Ruffolo RR, Yue T-L. Apoptosis and congestive heart failure. Trends Ca